GKOS files 8-K — Item 7.01 Regulation FD

Glaukos Corporation (GKOS), a $8.2B market cap ophthalmic medical technology firm, filed an 8-K SEC disclosure including Item 7.01 (Regulation FD) on May 4, 2026, with EDGAR acceptance timestamped 07:00:12 UTC, accessible via accession number 0001193125-26-202466.

What Was Filed

This filing falls under SEC Item 7.01, the plain-language category for disclosures of material nonpublic information made to comply with Regulation FD, which mandates companies publicly release critical updates to avoid selective disclosure to certain investors. This marks GKOS’s fifth SEC filing in the last 19 days, following an April 29, 2026 10-Q, two Schedule 13G filings, an earnings-related 8-K, and an April 16 ARS filing.

The Disclosure

For ophthalmic medical technology firms, Item 7.01 filings most commonly cover late-breaking clinical trial data, FDA regulatory decisions, updated commercial performance metrics, or strategic partnership announcements. Unlike combined 8-K items (e.g., 2.02 paired with 7.01 for earnings guidance), this filing only includes Item 7.01, making it a standalone FD-compliant material update unconnected to core financial filings like quarterly earnings or leadership changes.

Cross-Referenced Prior Signals

This filing follows high-profile insider transactions in the 90 days prior: On April 14, 2026, Chief Development Officer Navratil Tomas sold 2,093 shares across four separate transactions at an average price of $117.63 per share, generating total proceeds of $246,175. On April 3, 2026, all three named executive officers received in-kind share grants: President & COO Gilliam Joseph E received 3,169 shares valued at $347,322, CFO Thurman Alex R. received 1,589 shares valued at $174,154, and CEO Burns Thomas William received a $0-valued gift of 180,308 shares. Additional institutional context comes from the December 31, 2025 13F filing, which showed 339 institutional holders (a 14% quarter-over-quarter increase), with institutional ownership covering 99.8% of GKOS’s float, including 75 new institutional positions, 199 increased positions, 102 reduced positions, and 56 fully closed positions. The most recent analyst rating distribution, as of April 1, 2026, showed 3 Strong Buy, 10 Buy, and no Hold/Sell/Strong Sell ratings, a slight shift from March 1’s 3 Buy, 11 Hold, 1 Sell breakdown.

What This Filing Does NOT Tell Us

First, the specific content of the Item 7.01 disclosure, as the full EDGAR filing text is not parsed here. Second, no details on whether the update ties to GKOS’s existing product lines (e.g., iStent micro-bypass stents) or new pipeline candidates for glaucoma or retinal diseases, nor does it include forward-looking financial guidance. Third, there is no data on how this disclosure may impact near-term institutional positioning or analyst ratings, as the most recent institutional ownership data is from December 31, 2025, and the latest analyst ratings are from April 1, 2026.